S

Stenocare A/S
CSE:STENO

Watchlist Manager
Stenocare A/S
CSE:STENO
Watchlist
Price: 1.3 DKK -7.14% Market Closed
Market Cap: 26m DKK
Have any thoughts about
Stenocare A/S?
Write Note

Profitability Summary

Stenocare A/S's profitability score is 14/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

14/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

14/100
Profitability
Score
14/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Stenocare A/S

Revenue
3.1m DKK
Operating Expenses
-18.5m DKK
Operating Income
-15.4m DKK
Other Expenses
-1.4m DKK
Net Income
-16.8m DKK

Margins Comparison
Stenocare A/S Competitors

Country Company Market Cap Operating
Margin
Net
Margin
DK
Stenocare A/S
CSE:STENO
23.6m DKK
-493%
-538%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK
44%
35%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
28%
17%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
34%
19%
CH
Roche Holding AG
SIX:ROG
197.2B CHF
32%
20%
UK
AstraZeneca PLC
LSE:AZN
159B GBP
21%
13%
CH
Novartis AG
SIX:NOVN
169.7B CHF
31%
35%
US
Pfizer Inc
NYSE:PFE
149.4B USD
22%
7%
Country DK
Market Cap 23.6m DKK
Operating Margin
-493%
Net Margin
-538%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 729.3B USD
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 2.6T DKK
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 347.8B USD
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 248.3B USD
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 197.2B CHF
Operating Margin
32%
Net Margin
20%
Country UK
Market Cap 159B GBP
Operating Margin
21%
Net Margin
13%
Country CH
Market Cap 169.7B CHF
Operating Margin
31%
Net Margin
35%
Country US
Market Cap 149.4B USD
Operating Margin
22%
Net Margin
7%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Stenocare A/S Competitors

Country Company Market Cap ROE ROA ROCE ROIC
DK
Stenocare A/S
CSE:STENO
23.6m DKK
-71%
-51%
-63%
-51%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
197.2B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
159B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
169.7B CHF
45%
17%
24%
16%
US
Pfizer Inc
NYSE:PFE
149.4B USD
5%
2%
7%
8%
Country DK
Market Cap 23.6m DKK
ROE
-71%
ROA
-51%
ROCE
-63%
ROIC
-51%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 729.3B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 2.6T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 347.8B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 248.3B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 197.2B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country UK
Market Cap 159B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country CH
Market Cap 169.7B CHF
ROE
45%
ROA
17%
ROCE
24%
ROIC
16%
Country US
Market Cap 149.4B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
8%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top